New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond

References

• American Cancer SocietyDetailed guide: lung cancer – non-small cellWhat is non-small cell lung cancer?American Cancer Society2010 Available from: http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancerAccessed April 21, 2011
   Google Scholar
• National Comprehensive Cancer Network (NCCN)Clinical practice guidelines in OncologyTMNon-small cell lung cancer. V.2.2010National Comprehensive Cancer Network2011 Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfAccessed September 8, 2011
   Google Scholar
• CarmelietPJainRKAngiogenesis in cancer and other diseasesNature200040724925711001068
   PubMed Web of Science ®Google Scholar
• FolkmanJKlagsbrunMAngiogenic factorsScience19872354424472432664
   PubMed Web of Science ®Google Scholar
• KeedyVLSandlerABInhibition of angiogenesis in the treatment of non-small cell lung cancerCancer Sci2007981825183017892508
   PubMed Web of Science ®Google Scholar
• FerraraNKerbelRSAngiogenesis as a therapeutic targetNature200543896797416355214
   PubMed Web of Science ®Google Scholar
• LohelaMBryMTammelaTAlitaloKVEGFs and receptors involved in angiogenesis versus lymphangiogenesisCurr Opin Cell Biol20092115416519230644
   PubMed Web of Science ®Google Scholar
• PrestaMDell’EraPMitolaSMoroniERoncaRRusnatiMFibroblast growth factor/fibroblast growth factor receptor system in angiogenesisCytokine Growth Factor Rev20051615917815863032
   PubMed Web of Science ®Google Scholar
• CaoYCaoRHedlundEMRegulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathwaysJ Mol Med20088678578918392794
   PubMed Web of Science ®Google Scholar
• MurakamiMSimonsMFibroblast growth factor regulation of neovascularizationCurr Opin Hematol20081521522018391788
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRJrGatzemeierUFossellaFPhase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancerJ Clin Oncol2009274274428019652055
   PubMed Web of Science ®Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res2004647099710915466206
   PubMed Web of Science ®Google Scholar
• NEXAVAR (sorafenib) tablets, oral [package, insert]Wayne, NJBayer Health-Care Pharmaceuticals, Inc2009
   Google Scholar
• CarterCChenCBrinkCSorafenib is efficacious and tolerated in combination with cytostatic agents in preclinical models of human non-small cell lung carcinomaCancer Chemother Pharmacol20075918319516724239
   PubMed Web of Science ®Google Scholar
• MinamiHKawadaKEbiHPhase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumorsCancer Sci2008991492149818477034
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRJrGatzemeierUFossellaFPhase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancerJ Clin Oncol2009274274428019652055
   PubMed Web of Science ®Google Scholar
• SchillerJHLeeJWHannaNHTraynorAMCarboneDPA randomized discontinuation Phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501J Clin Oncol (Meeting Abstracts)20082615 Supplabstr 8014
   Web of Science ®Google Scholar
• SchillerJHFlahertyKTRedlingerMSorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: a Phase I subset analysisJ Clin Oncol (Meeting Abstracts)20062418 Supplabstr 7194
   Google Scholar
• ScagliottiGNovelloSvonPJPhase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancerJ Clin Oncol2010281835184220212250
   PubMed Web of Science ®Google Scholar
• Bayer HealthCare Pharmaceuticals Inc, Onyx Pharmaceuticals IncPhase 3 trial of Nexavar in first-line advanced non-small cell lung cancer does not meet primary endpoint of overall survival Press release2010614 Available from: http://www.onyx-pharm.com/view.cfm/685/Phase-3-Trial-of-Nexavar-in-First-Line-Advanced-Non-Small-Cell-Lung-Cancer-Does-Not-Meet-Primary-Endpoint-of-Overall-SurvivalAccessed August 9, 2011
   Google Scholar
• HerbstRSJohnsonDHMininbergEPhase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancerJ Clin Oncol2005232544255515753462
   PubMed Web of Science ®Google Scholar
• TonraJRDeeviDSCorcoranESynergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapyClin Cancer Res2006122197220716609035
   PubMed Web of Science ®Google Scholar
• LindJSDingemansAMGroenHJA multicenter, Phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancerClin Cancer Res2010163078308720395213
   PubMed Web of Science ®Google Scholar
• HerbstRSBlumenscheinGRJrKimESSorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trialJ Clin Oncol (Meeting Abstracts)20102815 Suppl abstr 7609
   Web of Science ®Google Scholar
• SUTENT^® (sunitinib malate) capsules, oral [package insert]New York, NYPfizer Inc2010
   Google Scholar
• NovelloSScagliottiGVRosellRPhase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancerBr J Cancer20091011543154819826424
   PubMed Web of Science ®Google Scholar
• SocinskiMANovelloSBrahmerJRMulticenter, Phase II trial of sunitinib in previously treated, advanced nonsmall-cell lung cancerJ Clin Oncol20082665065618235126
   PubMed Web of Science ®Google Scholar
• ReckMFrickhofenNCedresSSunitinib in combination with gemcitabine plus cisplatin for advanced nonsmall cell lung cancer: a Phase I dose-escalation studyLung Cancer2010
   Web of Science ®Google Scholar
• RobertFSandlerASchillerJHSunitinib in combination with docetaxel in patients with advanced solid tumors: a Phase I dose-escalation studyCancer Chemother Pharmacol201066466968020043166
   PubMed Web of Science ®Google Scholar
• PfizerA study in patients with non-small cell lung cancer testing if erlotinib plus SU011248 (sunitinib) is better than erlotinib alone (SUN1058)ClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2011 [updated August 26, 2011]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00265317. NLM identifier: NCT00265317Accessed September 12, 2011
   Google Scholar
• PfizerA study in patients with non-small cell lung cancer to test if erlotinib plus SU011248 is better than erlotinib aloneClinicalTrials gov [website on the Internet]Bethseda, MDUS National Library of Medicine2011 [updated July 6, 2011]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00457392. NLM identifier: NCT00457392Accessed September 12, 2011
   Google Scholar
• HennequinLFStokesESThomasAPNovel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitorsJ Med Chem2002451300131211881999
   PubMed Web of Science ®Google Scholar
• WedgeSROgilvieDJDukesMZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationCancer Res2002624645465512183421
   PubMed Web of Science ®Google Scholar
• HoldenSNEckhardtSGBasserRClinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumorsAnn Oncol2005161391139715905307
   PubMed Web of Science ®Google Scholar
• NataleRBBodkinDGovindanRVandetanib versus gefitinib in patients with advanced non-small cell lung cancer: results from a two-part, double-blind, randomized Phase II trialJ Clin Oncol2009272523252919332730
   PubMed Web of Science ®Google Scholar
• HeymachJVJohnsonBEPragerDRandomized, placebo-controlled Phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancerJ Clin Oncol2007254270427717878479
   PubMed Web of Science ®Google Scholar
• HerbstRSSunYEberhardtWEVandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, Phase 3 trialLancet Oncol7201011761962620570559
   PubMed Web of Science ®Google Scholar
• De BoerRArrietaOGottfriedMVandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind Phase III trial (ZEAL)J Clin Oncol (Meeting Abstracts)20092715 Supplabstr 8010
   Google Scholar
• NataleRBThongprasertSGrecoFAVandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind Phase III trial (ZEST)J Clin Oncol (Meeting Abstracts)20092715 Supplabstr 8009
   Web of Science ®Google Scholar
• LeeJHirshVParkKVandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind Phase III trial (ZEPHYR)J Clin Oncol201028abstr 7525
   Web of Science ®Google Scholar
• HeckmanCAHolopainenTWirzeniusMThe tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesisCancer Res2008684754476218559522
   PubMed Web of Science ®Google Scholar
• WedgeSRKendrewJHennequinLFAZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerCancer Res2005654389440015899831
   PubMed Web of Science ®Google Scholar
• LaurieSAGauthierIArnoldAPhase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials groupJ Clin Oncol2008261871187818398152
   PubMed Web of Science ®Google Scholar
• GossGShepherdFALaurieSA Phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials GroupEur J Cancer20094578278819091548
   PubMed Web of Science ®Google Scholar
• GossGDArnoldAShepherdFARandomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 studyJ Clin Oncol201028495519917841
   PubMed Web of Science ®Google Scholar
• GadgeelSMWozniakAEdelmanMJCediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC)J Clin Oncol (Meeting Abstracts)20092715 Supple19007
   Web of Science ®Google Scholar
• DyGKMandrekarSJNelsonGDA randomized Phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC)J Clin Oncol (Meeting Abstracts)20102815 Supplabstr 7603
   Web of Science ®Google Scholar
• ChoueiriTKAxitinib, a novel anti-angiogenic drug with promising activity in various solid tumorsCurr Opin Investig Drugs20089658671
   PubMed Web of Science ®Google Scholar
• KellyRJRixeOAxitinib (AG-013736)Recent Results Cancer Res2010184334420072829
   PubMedGoogle Scholar
• MartinLPKozloffMFKrzakowskiMAxtinib (AG-013736; AG) combined with chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) and other solid tumorsJ Clin Oncol (Meeting Abstracts)20092715 Supplabstr 3559
   Google Scholar
• RugoHSHerbstRSLiuGPhase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical resultsJ Clin Oncol2005235474548316027439
   PubMed Web of Science ®Google Scholar
• SchillerJHLarsonTOuSHEfficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a Phase II studyJ Clin Oncol2009273836384119597027
   PubMed Web of Science ®Google Scholar
• SchutzFAChoueiriTKSternbergCNPazopanib: clinical development of a potent anti-angiogenic drugCrit Rev Oncol Hematol201177316317120456972
   PubMed Web of Science ®Google Scholar
• HurwitzHIDowlatiASainiSPhase I trial of pazopanib in patients with advanced cancerClin Cancer Res2009154220422719509175
   PubMed Web of Science ®Google Scholar
• AltorkiNGuarinoMLeePPreoperative treatment with pazopanib (GW786034) a multikinase angiogenesis inhibitor in early stage non-small cell lung cancer (NSCLC): a proof-of-concept Phase II studyJ Clin Oncol (Meeting Abstracts)20082615 Supplabstr 7557
   Web of Science ®Google Scholar
• CarlomagnoFVitaglianoDGuidaTZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks, oncogenic RET kinaseCancer Res2002627284729012499271
   PubMed Web of Science ®Google Scholar
• PolverinoACoxonAStarnesCAMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenograftsCancer Res2006668715872116951187
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRJrReckampKStephensonGJPhase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancerClin Cancer Res20101627929020028752
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRKabbinavarFFMenonHRandomized, open-label Phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC)J Clin Oncol (Meeting Abstracts)20102815 Supplabstr 7528
   Web of Science ®Google Scholar
• AmgenMONET1-MOtesanib NSCLC Efficacy and Tolerability StudyClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2007 [updated September 1, 2011]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00460317. NLM identifier: NCT00460317Accessed October 4, 2011
   Google Scholar
• HilbergFRothGJKrssakMBIBF1120: triple angiokinase inhibitor with sustained receptor blockade and good anti-tumor efficacyCancer Res200868124774478218559524
   PubMed Web of Science ®Google Scholar
• HilbergFBrandstetterIRothGJIn vitro and in vivo efficacy of BIBF 1120, a small molecule triple angiokinase inhibitor, in combination with taxanes. Proceedings AACR-NCI-EORTCInt Conf Mol Targets Cancer Ther200559A19
   Google Scholar
• StopferPRothWMrossKBPharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) inadvanced cancer patientsEur J Cancer Suppl200641226
   Web of Science ®Google Scholar
• LeeCPTaylorNJAttardGA Phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)J Clin Oncol (Meeting Abstracts)20062418 Supplabstr 3015
   Web of Science ®Google Scholar
• KanedaHOkamotoISatohTPhase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumours (and presentation)Eur J Cancer Suppl200972abstr 1243
   Web of Science ®Google Scholar
• HannaNEllisPStopferPA Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancerJ Thoracic Oncol200728S717
   Google Scholar
• CamidgeDRConklingPStephensonJShapiroDA Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC)J Thoracic Oncol200728S730
   Google Scholar
• Von PawelJKaiserREschbachCEfficacy, safety and pharmacokinetic (PK) results of a Phase II study with the triple angiokinase inhibitor BIBF 1120 in patients suffering from advanced non small cell lung cancer (NSCLC)J Thoracic Oncol200834S61
   Google Scholar
• ReckMKaiserREschbachCA Phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancerAnn Oncol20112261374138121212157
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govLUME-Lung 1: BIBF 1120 plusdocetaxel as compared to placebo plus docetaxel in 2nd line non small cell lung cancer2008 Available from: http://clinicaltrials.gov/ct2/show/NCT00805194?term=BIBF+1120&rank=6Accessed April 15, 2009
   Google Scholar
• ClinicalTrials.govLUME-Lung 2: BIBF 1120 plus pemetrexed compared to placebo plus pemetrexed in 2nd line nonsquamous NSCLC2008 Available from: http://clinicaltrials.gov/ct2/show/NCT00806819?term=BIBF+1120&rank=4Accessed April 15, 2009
   Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer20094522824719097774
   PubMed Web of Science ®Google Scholar